Key facts
- It has raised $226.3M.
- Notable investors include Mana Ventures, Alexandria Venture Investments, Madrona Venture Group, NVentures (Santa Clara), Two Sigma Ventures — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Terray Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Terray Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Terray Therapeutics
Operator of an Artificial Intelligence driven biotechnology company intended to provide advanced machine learning and AI models to speed drug discovery and development. The company's internal pipeline is focused on developing small-molecule drugs in immunology, by use of artificial intelligence, synthetic chemistry, automation, and nanotechnology to generate the chemical datasets using ultra-dense microarray technology that works seamlessly with the integrated machine learning and computational platform to systematically map biochemical interactions between small molecules and causes of disease and iterative cycles of virtual molecular design and experimentation power AI and machine learning models that in turn guide the next cycle of design, enabling doctors to derive insights to predict and create drugs for patients in need.
- Sector
- Healthcare
- HQ
- Monrovia, CA, United States
- Founded
- 2018
- Employees
- 122
- Website
- terraytx.com/
- Ownership
- Privately Held (backing)
Terray Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terray Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terray Therapeutics in its N-PORT filings yet. We sweep new filings monthly.